NEXALIN TECHNOLOGY INC

NXLNASDAQ

🏆 #4694 by market capEarnings Sep 2US Equity

$0.36▲ $0.00 (+1.03%)

Live

1h—

24h▲ 1.0%

7d▼ 3.8%

14d▼ 4.8%

30d▼ 8.4%

1y▼ 59.4%

🏦Market Cap

$8M

Small Cap

📈Revenue Growth (YoY)

+78.8%

High Growth

📊Gross Margin

-102.9%

Thin

💵FCF Margin

-1933.1%

Thin

⚖️P/S Ratio

28.9x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $0.36 – $0.36
52-Week Range: $0.31 – $2.00
Volume: $4.03B
Avg Volume: $5.12B
Shares Outstanding: 22.0M
Next Earnings: Sep 28, 2026

Fundamentals Snapshot

Annual Revenue: $301,647
Last Q Revenue: $14,950
P/E Ratio: -0.8
P/S Ratio: 28.9x
EPS (TTM): $-0.42
Dividend Yield: 0.00%

Why Investors Own NXL

✓High-growth profile — revenue up +14.6% YoY with expanding US Equity exposure.
✓Healthy economics — 65% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$301,647▲ +10.7% YoY

Gross Margin (TTM)

64.7%▲ +2.9% YoY

Operating Income (TTM)

$24,433▲ +10.7% YoY

Free Cash Flow (TTM)

$31,975▲ +10.7% YoY

About NEXALIN TECHNOLOGY INC

Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.

🦦